Affordable Access

deepdyve-link
Publisher Website

Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy

Authors
  • Fujiyuki, Tomoko1
  • Amagai, Yosuke1
  • Shoji, Koichiro1
  • Kuraishi, Takeshi2
  • Sugai, Akihiro1
  • Awano, Mutsumi1
  • Sato, Hiroki1
  • Hattori, Shosaku2
  • Yoneda, Misako1
  • Kai, Chieko1
  • 1 Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • 2 Amami Laboratory of Injurious Animals, The Institute of Medical Science, The University of Tokyo, 802 Tean-Sude, Setouchisho, Oshima-gun, Kagoshima 894-1531, Japan
Type
Published Article
Journal
Molecular Therapy Oncolytics
Publisher
American Society of Gene & Cell Therapy
Publication Date
Sep 30, 2020
Volume
19
Pages
127–135
Identifiers
DOI: 10.1016/j.omto.2020.09.007
PMID: 33145396
PMCID: PMC7585052
Source
PubMed Central
Keywords
License
Unknown

Abstract

Triple negative breast cancer (TNBC) is one of the most refractory breast cancer types. A recombinant measles virus, rMV-SLAMblind, infected nectin-4-positive TNBC cells and significantly suppressed the tumor growth in xenograft models. Thus, rMV-SLAMblind is a promising candidate as a therapeutic agent for TNBC.

Report this publication

Statistics

Seen <100 times